Aipalolitovorelizumab (Not yet branded)
Immunotherapy
Description
Aipalolitovorelizumab (QL1706) is an immunotherapy agent being evaluated specifically for microsatellite stable (MSS) metastatic colorectal cancer, a subset that typically shows poor response to conventional immune checkpoint inhibitors. The drug is designed to overcome immune resistance in "cold" tumors by enhancing immune system activation against cancer cells. Clinical data suggests potential efficacy when combined with bevacizumab and standard chemotherapy or with fruquintinib in patients with BRAF mutations and MSS tumors.
Mechanism of Action
This agent appears to work through immune system modulation to enhance T-cell activation and tumor recognition in microsatellite stable colorectal cancers. The specific molecular target involves checkpoint inhibition pathways designed to convert immunologically "cold" MSS tumors into "hot" tumors that can be recognized and attacked by the immune system.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.